Stephen V Liu Shared Real-World Evidence from the AYAME Study of Durvalumab in NSCLC
Stephen V Liu, Director of Thoracic Oncology, Chief, Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a recent article by Hirotsugu Kenmotsu et al., published in the Journal of Thoracic Oncology:
“Prospective real-world AYAME study of durvalumab post chemoradiation for NSCLC in Japan, Journal of Thoracic Oncology. rwPFS 23.2m consistent with other reports. ILD seen in 75.7%: 35% G1, 28% G2, 11% G3, 2% G5. Only 3% risk of ILD between durvalumab and next treatment.
These rates are a bit higher than the trial but in line with other real-world studies, though this is one of the largest efforts. Other notable toxicities include thyroid dysfunction in 12.5% (median onset 87d), hepatic dysfunction in 7.2% (median onset 43d), colitis in 2%.”
Title: Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer in Japan: A Multicenter Prospective Study (AYAME)
Authors: Hirotsugu Kenmotsu, Yoshinobu Saito, Kiichiro Ninomiya, Shinya Uematsu, Burak Akdemir, Ayako Fukui, Ryo Koto, Masakazu Fujiwara, Chikako Iwao, Hiroshi Kitagawa, Ichiro Yoshino, Akihiko Gemma, Tetsuya Mitsudomi, Nobuyuki Yamamoto
Read the Full Article at Journal of Thoracic Oncology.
More posts featuring Stephen V Liu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023